Italy· 033866070
FANHDI*1 flaconcino polv e solv EV 1500 Unita' Internazionali + 1800 Unita' Internazionali 15 ml + 1 siringa preriempita
A medicinal product containing fattore viii di coagulazione del sangue umano/fattore di von willebrand, registered in Italy by INSTITUTO GRIFOLS S.A., on the national reimbursement list.
Checked against the register on
Informational only — not a medical device.
The record
At a glance
- Active substance
- Fattore VIII di coagulazione del sangue umano/Fattore di Von Willebrand
- Manufacturer
- INSTITUTO GRIFOLS S.A.
- Country
- Italy (IT)
- ATC code
- —
- Reimbursed
- Yes
- Last checked
- June 4, 2026
Packs & prices · 1
1 priced- aic033866070FANHDI*1 flaconcino polv e solv EV 1500 Unita' Internazionali + 1800 Unita' Internazionali 15 ml + 1 siringa preriempitaEUR 1157.61
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b7d80632-3296-4835-9abb-a8c13b170de4 GET /v1/drugs/b7d80632-3296-4835-9abb-a8c13b170de4?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"price": 1157.61,
"source": "aifa",
"currency": "EUR",
"strength": "FATTORE VIII UMANO DI COAGULAZIONE+FATTORE DI VON WILLEBRAND 1.500UI +1800UI 15ML 1 UNITA' USO PARENTERALE",
"substance": "Fattore VIII di coagulazione del sangue umano/Fattore di Von Willebrand",
"equivalence_group": "LRB",
"transparency_flag": null
}See everything about fattore viii di coagulazione del sangue umano/fattore di von willebrand.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.